...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Message: About that 18% to 21% RRR...

"Our 18 to 21% RRR is actually well ahead of many other cardiovascular disease drugs.  I know this is not an apples to apples comparison...but take it for what it is."

Yes, 18-21% is really good, especially in the high-risk diabetic low-HDL recent ACS patient population. Too bad BETonMACE was underpowered to hit w/ statistical significance at this lower RRR.


New Message
Please login to post a reply